Emmerich B, Emslander H P, Milatovic D, Hallek M, Pachmann K
Medizinische Klinik Innenstadt, Universität München, Federal Republic of Germany.
Lung. 1990;168 Suppl:726-31. doi: 10.1007/BF02718200.
Our findings demonstrate that Broncho-Vaxom (BV) displays possibly via the gut-associated immune system different effects on the lymphatic system of the lung: a positive influence on the helper/suppressor T-lymphocyte balance, an increase of gamma interferon, a stimulation of the reduced alveolar macrophage activity, and a regulation of BAL IgA to a distinct level whereby the serum IgE is reduced. By these effects BV is able to modulate impaired local and systemic immune function. The observed relationship between the inflammation score and the BAL fluid composition supports the view that the improvement of the mucosa lesion found in nearly all of our patients with chronic bronchitis occurs as the result of the pleiotropic immunomodulating effects of Broncho-Vaxom.
我们的研究结果表明，泛福舒（BV）可能通过肠道相关免疫系统对肺部淋巴系统产生不同影响：对辅助/抑制性T淋巴细胞平衡有积极影响，增加γ干扰素，刺激降低的肺泡巨噬细胞活性，并将支气管肺泡灌洗（BAL）液中的免疫球蛋白A（IgA）调节至特定水平，从而降低血清免疫球蛋白E（IgE）。通过这些作用，BV能够调节受损的局部和全身免疫功能。观察到的炎症评分与BAL液成分之间的关系支持了这样一种观点，即我们几乎所有慢性支气管炎患者中发现的黏膜病变改善是泛福舒多效免疫调节作用的结果。
